Top

Published in:

01-01-2016 | Focussed Research Review

Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies

Authors: Gaetano Finocchiaro, Serena Pellegatta

Published in: Cancer Immunology, Immunotherapy | Issue 1/2016

Abstract

Different approaches have been explored to raise effective antitumor responses against glioblastoma (GBM), the deadliest of primary brain tumors. In many clinical studies, cancer vaccines have been based on dendritic cells (DCs) loaded with peptides, representing one or more specific tumor antigens or whole lysates as a source of multiple antigens. Randomized clinical trials using DCs are ongoing, and results of efficacy are not yet available. Such strategies are feasible and safe; however, immune-suppressive microenvironment, absence of appropriate specific epitopes to target, and cancer immunoediting can limit their efficacy. The aim of this review is to describe how the definition of novel and more specific targets may increase considerably the possibility of successful DC immunotherapy. By proposing to target glioblastoma stem-like cells (GSCs), the immune response will be pointed to eradicating factors and pathways highly relevant to GBM biology. Preclinical observations on efficacy, and preliminary results of immunotherapy trials, encourage exploring the clinical efficacy of DC immunotherapy in GBM patients using high-purity, GSC-loaded DC vaccines.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 PubMedCrossRef

Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570. doi:10.1126/science.1203486 PubMedCrossRef

Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10:909–915. doi:10.1038/nm1100 PubMedPubMedCentralCrossRef

Siesjö P, Visse E, Sjögren HO (1996) Cure of established, intracerebral rat gliomas induced by therapeutic immunizations with tumor cells and purified APC or adjuvant IFN-gamma treatment. J Immunother Emphas Tumor Immunol 19:334–345CrossRef

Liau LM, Black KL, Prins RM et al (1999) Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 90:1115–1124. doi:10.3171/jns.1999.90.6.1115 PubMedCrossRef

Witham TF, Erff ML, Okada H et al (2002) 7-Hydroxystaurosporine-induced apoptosis in 9L glioma cells provides an effective antigen source for dendritic cells and yields a potent vaccine strategy in an intracranial glioma model. Neurosurgery 50(6):1327–1335PubMed

Akasaki Y, Kikuchi T, Homma S et al (2001) Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 24:106–113CrossRef

Heimberger AB, Crotty LE, Archer GE et al (2000) Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16–25PubMedCrossRef

Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M (2002) A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613–621PubMed

10.

Kikuchi T, Akasaki Y, Abe T, Ohno T (2002) Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 51:424–430PubMedCrossRef

11.

Ni HT, Spellman SR, Jean WC et al (2001) Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 51:1–9PubMedCrossRef

12.

Okada H, Tahara H, Shurin MR et al (1998) Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. Int J Cancer 78:196–201PubMedCrossRef

13.

Pellegatta S, Finocchiaro G (2005) Cell therapies in neuro-oncology. Neurol Sci 26(Suppl 1):S43–S45. doi:10.1007/s10072-005-0405-x PubMedCrossRef

14.

Pellegatta S, Poliani PL, Corno D et al (2006) Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res 28:527–531. doi:10.1179/016164106X116809 PubMedCrossRef

15.

De Vleeschouwer S, Van Calenbergh F, Demaerel P et al (2004) Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 100:492–497PubMed

16.

Rutkowski S, De Vleeschouwer S, Kaempgen E et al (2004) Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 91:1656–1662PubMedPubMedCentral

17.

Wheeler CJ, Das A, Liu G et al (2004) Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 10:5316–5326PubMedCrossRef

18.

Yamanaka R, Abe T, Yajima N et al (2003) Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 89:1172–1179PubMedPubMedCentralCrossRef

19.

Yamanaka R, Homma J, Yajima N et al (2005) Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 11:4160–4167. doi:10.1158/1078-0432.CCR-05-0120 PubMedCrossRef

20.

Yu JS, Liu G, Ying H et al (2004) Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 64:4973–4979. doi:10.1158/0008-5472.CAN-03-3505 PubMedCrossRef

21.

22.

Liau LM, Prins RM, Kiertscher SM et al (2005) Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 11:5515–5525. doi:10.1158/1078-0432.CCR-05-0464 PubMedCrossRef

23.

Polyzoidis S, Ashkan K (2014) Dendritic cell immunotherapy for glioblastoma. Expert Rev Anticancer Ther 14:761–763. doi:10.1586/14737140.2014.921571 PubMedCrossRef

24.

Anguille S, Smits EL, Lion E et al (2014) Clinical use of dendritic cells for cancer therapy. Lancet Oncol 15:e257–e267. doi:10.1016/S1470-2045(13)70585-0 PubMedCrossRef

25.

Finocchiaro G, Pellegatta S (2014) Perspectives for immunotherapy in glioblastoma treatment. Curr Opin Oncol 26(6):608–614. doi:10.1097/CCO.0000000000000135 PubMedCrossRef

26.

Lasky JL, Panosyan EH, Plant A et al (2013) Autologous tumor lysate-pulsed dendritic cell immunotherapy for pediatric patients with newly diagnosed or recurrent high-grade gliomas. Anticancer Res 33:2047–2056PubMedPubMedCentral

27.

Pellegatta S, Eoli M, Frigerio S et al (2013) The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates. Oncoimmunology 2:e23401. doi:10.4161/onci.23401 PubMedPubMedCentralCrossRef

28.

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G (2008) Immunological aspects of cancer chemotherapy. Nat Rev Immunol 8:59–73. doi:10.1038/nri2216 PubMedCrossRef

29.

Galluzzi L, Senovilla L, Zitvogel L, Kroemer G (2012) The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 11:215–233. doi:10.1038/nrd3626 PubMedCrossRef

30.

Sampson JH, Aldape KD, Archer GE et al (2011) Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol 13:324–333. doi:10.1093/neuonc/noq157 PubMedPubMedCentralCrossRef

31.

Eoli M, Pellegatta S, Frigerio S et al (2014) Association of increased progression-free survival in primary glioblastomas with lymphopenia at baseline and activation of NK and NKT cells after dendritic cell immunotherapy. In: ASCO Annual Meeting. J Clin Oncol 32:5 (suppl; abstr 2087)

32.

Pellegatta S, Eoli M, Cantini G et al (2014) P02.03 * Increased count of NK and NKT cells are associated with prolonged survival in primary glioblastoma patients treated with dendritic cell immunotherapy in combination with radio- and chemo-therapy. Neuro Oncol 16:ii33. doi:10.1093/neuonc/nou174.119 (poster) PubMedCentralCrossRef

33.

Singh SK, Hawkins C, Clarke ID et al (2004) Identification of human brain tumour initiating cells. Nature 432:396–401. doi:10.1038/nature03128 PubMedCrossRef

34.

Quintana E, Shackleton M, Sabel MS et al (2008) Efficient tumour formation by single human melanoma cells. Nature 456:593–598. doi:10.1038/nature07567 PubMedPubMedCentralCrossRef

35.

Beier D, Hau P, Proescholdt M et al (2007) CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010–4015. doi:10.1158/0008-5472.CAN-06-4180 PubMedCrossRef

36.

Ben-Porath I, Thomson MW, Carey VJ et al (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40:499–507. doi:10.1038/ng.127 PubMedPubMedCentralCrossRef

37.

Chen R, Nishimura MC, Bumbaca SM et al (2010) A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17:362–375. doi:10.1016/j.ccr.2009.12.049 PubMedCrossRef

38.

Pellegatta S, Poliani PL, Corno D et al (2006) Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas. Cancer Res 66:10247–10252. doi:10.1158/0008-5472.CAN-06-2048 PubMedCrossRef

39.

Ghods AJ, Irvin D, Liu G et al (2007) Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells 25:1645–1653. doi:10.1634/stemcells.2006-0624 PubMedCrossRef

40.

Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821–5828PubMed

41.

Tunici P, Bissola L, Lualdi E et al (2004) Genetic alterations and in vivo tumorigenicity of neurospheres derived from an adult glioblastoma. Mol Cancer 3:25. doi:10.1186/1476-4598-3-25 PubMedPubMedCentralCrossRef

42.

Lee J, Kotliarova S, Kotliarov Y et al (2006) Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9:391–403. doi:10.1016/j.ccr.2006.03.030 PubMedCrossRef

43.

Verhaak RGW, Hoadley KA, Purdom E et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110. doi:10.1016/j.ccr.2009.12.020 PubMedPubMedCentralCrossRef

44.

Soeda A, Park M, Lee D et al (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28:3949–3959. doi:10.1038/onc.2009.252 PubMedCrossRef

45.

Bhat KPL, Balasubramaniyan V, Vaillant B et al (2013) Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell 24:331–346. doi:10.1016/j.ccr.2013.08.001 PubMedCrossRef

46.

Sottoriva A, Spiteri I, Piccirillo SGM et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110:4009–4014. doi:10.1073/pnas.1219747110 PubMedPubMedCentralCrossRef

47.

Bonavia R, Inda M-M, Cavenee WK, Furnari FB (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71:4055–4060. doi:10.1158/0008-5472.CAN-11-0153 PubMedPubMedCentralCrossRef

48.

Reardon DA (2015) Wen PY (2015) Glioma in 2014: unravelling tumour heterogeneity-implications for therapy. Nat Rev Clin Oncol 12(2):69–70. doi:10.1038/nrclinonc.2014.223 PubMedCrossRef

49.

Stieber D, Golebiewska A, Evers L et al (2014) Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol 127:203–219. doi:10.1007/s00401-013-1196-4 PubMedPubMedCentralCrossRef

50.

Di Tomaso T, Mazzoleni S, Wang E et al (2010) Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 16:800–813. doi:10.1158/1078-0432.CCR-09-2730 PubMedPubMedCentralCrossRef

51.

Wei J, Barr J, Kong L-Y et al (2010) Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9:67–78. doi:10.1158/1535-7163.MCT-09-0734 PubMedPubMedCentralCrossRef

52.

Wei J, Wu A, Kong L-Y et al (2011) Hypoxia potentiates glioma-mediated immunosuppression. PLoS One 6:e16195. doi:10.1371/journal.pone.0016195 PubMedPubMedCentralCrossRef

53.

Wu A, Wei J, Kong L-Y et al (2010) Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol 12:1113–1125. doi:10.1093/neuonc/noq082 PubMedPubMedCentralCrossRef

54.

Alizadeh D, Zhang L, Brown CE et al (2010) Induction of anti-glioma natural killer cell response following multiple low-dose intracerebral CpG therapy. Clin Cancer Res 16:3399–3408. doi:10.1158/1078-0432.CCR-09-3087 PubMedPubMedCentralCrossRef

55.

Castriconi R, Daga A, Dondero A et al (2009) NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J Immunol 182:3530–3539. doi:10.4049/jimmunol.0802845 PubMedCrossRef

56.

Brown CE, Starr R, Martinez C et al (2009) Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. Cancer Res 69:8886–8893. doi:10.1158/0008-5472.CAN-09-2687 PubMedPubMedCentralCrossRef

57.

Pallini R, Ricci-Vitiani L, Banna GL et al (2008) Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14:8205–8212. doi:10.1158/1078-0432.CCR-08-0644 PubMedCrossRef

58.

De Bacco F, Casanova E, Medico E et al (2012) The MET oncogene is a functional marker of a glioblastoma stem cell subtype. Cancer Res 72:4537–4550. doi:10.1158/0008-5472.CAN-11-3490 PubMedCrossRef

59.

Sampson JH, Heimberger AB, Archer GE et al (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729. doi:10.1200/JCO.2010.28.6963 PubMedPubMedCentralCrossRef

60.

Xu Q, Liu G, Yuan X et al (2009) Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells 27:1734–1740. doi:10.1002/stem.102 PubMedCrossRef

61.

De Rosa A, Pellegatta S, Rossi M et al (2012) A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One 7:e52113. doi:10.1371/journal.pone.0052113 PubMedPubMedCentralCrossRef

62.

Cantini G, Pisati F, Pessina S et al (2012) Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. Oncoimmunology 1:884–893. doi:10.4161/onci.20637 PubMedPubMedCentralCrossRef

63.

Favaro R, Appolloni I, Pellegatta S et al (2014) SOX2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. Cancer Res 74:1833–1844. doi:10.1158/0008-5472.CAN-13-1942 PubMedCrossRef

64.

Park D, Xiang AP, Mao FF et al (2010) Nestin is required for the proper self-renewal of neural stem cells. Stem Cells 28:2162–2171. doi:10.1002/stem.541 PubMedCrossRef

65.

Mehta S, Huillard E, Kesari S et al (2011) The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 19:359–371. doi:10.1016/j.ccr.2011.01.035 PubMedPubMedCentralCrossRef

66.

Vik-Mo EO, Nyakas M, Mikkelsen BV et al (2013) Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 62:1499–1509. doi:10.1007/s00262-013-1453-3 PubMedPubMedCentralCrossRef

67.

Ignatova TN, Kukekov VG, Laywell ED et al (2002) Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193–206. doi:10.1002/glia.10094 PubMedCrossRef

68.

Phuphanich S, Wheeler CJ, Rudnick JD et al (2013) Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 62:125–135. doi:10.1007/s00262-012-1319-0 PubMedPubMedCentralCrossRef

69.

Orzan F, Pellegatta S, Poliani PL et al (2011) Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells. Neuropathol Appl Neurobiol 37:381–394. doi:10.1111/j.1365-2990.2010.01132.x PubMedCrossRef

70.

Speranza MC, Frattini V, Pisati F et al (2012) NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Abstract 3:723–734

71.

Frattini V, Pisati F, Speranza MC et al (2012) FOXP3, a novel glioblastoma proliferation and migration affects. Abstract 3:1146–1157

72.

Patanè M, Porrati P, Bottega E et al (2013) Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres. Mol Cancer 12:160. doi:10.1186/1476-4598-12-160 PubMedPubMedCentralCrossRef

73.

Nava S, Dossena M, Pogliani S et al (2012) An optimized method for manufacturing a clinical scale dendritic cell-based vaccine for the treatment of glioblastoma. PLoS One 7:e52301. doi:10.1371/journal.pone.0052301 PubMedPubMedCentralCrossRef

74.

Parsons DW, Jones S, Zhang X et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812. doi:10.1126/science.1164382 PubMedPubMedCentralCrossRef

75.

Kim H, Zheng S, Amini SS et al (2015) Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res 25(3):316–327. doi:10.1101/gr.180612.114 PubMedPubMedCentralCrossRef

Title: Immunotherapy with dendritic cells loaded with glioblastoma stem cells: from preclinical to clinical studies
Authors: Gaetano Finocchiaro
Serena Pellegatta
Publication date: 01-01-2016
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 1/2016
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-015-1754-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Deficiency of IL-17A, but not the prototypical Th17 transcription factor RORγt, decreases murine spontaneous intestinal tumorigenesis

“Cancer Bio-Immunotherapy in Siena”: Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9–11, 2014

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

Low intratumoral regulatory T cells and high peritumoral CD8+ T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pancreatectomy

Aminoacyl-tRNA synthetase-interacting multifunctional protein 1 suppresses tumor growth in breast cancer-bearing mice by negatively regulating myeloid-derived suppressor cell functions

Phloretin increases the anti-tumor efficacy of intratumorally delivered heat-shock protein 70 kDa (HSP70) in a murine model of melanoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer